Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877344 | 0.90 | SCN9A (0.37) | SCN9ASLC8A1MEN1NPC1RAB9A | |
| SCHEMBL3931763 | 0.89 | GRIN2B (0.39) | KMT2AALOX5APFEN1SMOGRIN2B | |
| SCHEMBL4876035 | 0.88 | GRIN2B (0.39) | ALOX5APFEN1SMOGRIN2BHRH1 | |
| SCHEMBL4877357 | 0.88 | KCNH2 (0.34) | SCN9ASLC8A1 | |
| SCHEMBL4877145 | 0.88 | GRIN2B (0.37) | MEN1NPC1RAB9AKMT2ASMO | |
| SCHEMBL4874831 | 0.87 | ALDH1A1 (0.36) | SCN9ASLC8A1NPC1RAB9ASMO | |
| SCHEMBL4866924 | 0.87 | KCNH2 (0.34) | SCN9ASLC8A1 | |
| SCHEMBL4866857 | 0.87 | KCNH2 (0.34) | SCN9ASLC8A1 | |
| SCHEMBL4870793 | 0.86 | CBX7 (0.37) | KMT2ASMOGRIN2BHRH1 | |
| SCHEMBL4875214 | 0.85 | KMT2A (0.33) | MEN1NPC1RAB9AKMT2AALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | SCN9A 2977/4885SLC8A1 3881/4885MEN1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.